Device Trial Radar · NCT05832749
Comparison of the Safety and Efficacy of Ophtesis Bio 3% With a Similar 3% Sodium Hyaluronate OVD
Last checked: Nov 20, 2026Latest source record: Apr 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
296
Planned (sponsor's estimate)
Start
Aug 23, 2022
Primary completion
Apr 2023
Study completion May 2023
Sponsor
- Lead sponsor
- Gemini Eye ClinicNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 27, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, randomized, subject/evaluator-masked post market clinical study at up to 2 sites at Gemini eye clinic in Czech Republic. Randomization will be done by the eye surgeon. The purpose of this post market clinical trial is to compare the safety and efficacy of Ophtesis Bio 3% with a similar 3% sodium hyaluronate OVD in routine cataract surgery.
Conditions
- Bilateral Cataract
- Unilateral Cataract
Interventions
Ophtesis Bio 3% ophthalmic viscosurgical deviceDevice
Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.
Healon Endocoat 3% ophthalmic viscosurgical deviceDevice
Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including: * Cataract surgery with an intraocular lens * Cataract surgery without an intraocular lens * Secondary intraocular lens implantation Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular pressure (IOP)Time frame: 7 days
- Surgeon questionnaireTime frame: first day
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Gemini Eye Clinic
Průhonice, Czechia · Recruiting
Gemini Eye Clinic
Vyškov, Czechia · Completed
Gemini Eye Clinic
Zlín, Czechia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.